About Standigm
Standigm is a leading healthcare AI company that leverages artificial intelligence for drug discovery and development. Founded in 2015, the company aims to revolutionize the traditional drug discovery lifecycle by applying its AI technologies across various stages, including target discovery, hit identification, hit-to-lead, and lead optimization. Standigm’s proprietary AI platforms, such as Standigm ASK™ for novel target identification and Standigm BEST™ for novel compound generation, are designed to accelerate the development of first-in-class and best-in-class drug candidates.
For physicians, Standigm’s approach means potentially faster and more efficient identification of novel therapeutic targets and the design of new chemical structures, which could lead to a more robust pipeline of innovative treatments. The company’s workflow AI, Standigm Magic™, integrates these platforms to streamline the process from target discovery to lead compound series, aiming to complete this phase in an average of seven months. Standigm also offers AI platform services, including QIP-ADMET for predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity, SPICA for novelty assessment, STELLA for hit-to-lead optimization, and ASK-LLM for knowledge graph-to-text generation, to empower partners in accelerating their drug discovery processes.
Focus Areas
Business Intelligence
| Key Investors | SK Holdings, Kakao Ventures, LB Investment, Atinum Investment, IMM Investment, Stonebridge Ventures, KDB Bank, Shinhan Bank |
| Partnerships | SK Biopharmaceuticals, HK inno.N, CJ CheilJedang, Lunit, Hanmi Pharmaceutical |
| Acquisitions | unknown |
| Technology | AI operating system (Standigm AI), deep learning, machine learning, proprietary algorithms for drug discovery |
What Physicians Need to Know
For physicians, Standigm's AI-driven platforms offer the potential for faster identification of novel drug targets and the development of first-in-class compounds, potentially leading to new therapeutic options for challenging diseases like oncology and Parkinson's. Their drug repurposing efforts could also uncover new uses for existing medications, accelerating treatment availability. The explainability of their AI models means that the hypotheses generated are testable and can lead to actionable validation plans, which can be valuable for understanding the underlying biology and clinical implications of potential drug candidates.
Standigm offers AI SaaS & API solutions, including QIP-ADMET for ADMET prediction, SPICA for novelty assessment, STELLA for hit-to-lead optimization, and ASK-LLM for knowledge graph-to-text generation. They actively seek collaboration with pharmaceutical companies and universities for novel drug discovery and are looking to partner with Big Tech companies to expand their database and develop further technology. This suggests potential for integration of their AI platforms and data with external research and development pipelines.
What the Web Says
Standigm is a Seoul-based AI drug discovery company that utilizes AI SaaS and API solutions for target discovery, lead design, repurposing, and molecular generation. The company claims its approach can cut time and cost by approximately 30% in the early drug discovery pipeline. While Standigm has engaged in collaborations with Korean pharmaceutical companies and research institutions, and has raised significant funding, there is no verifiable evidence of a Standigm-originated molecule having reached clinical development or any partnerships with disclosed financial figures.
Overall: MixedStrengths
- Offers state-of-the-art AI SaaS & API solutions for drug discovery.
- Claims to cut time and cost by roughly 30% in the early pipeline.
- Engaged in collaborations with pharmaceutical companies and research institutions.
- Has raised approximately USD 70 million across five funding rounds.
- Workflow AI covers the full early pipeline, including target discovery, lead design, repurposing, and molecular generation.
Limitations
- No verifiable Standigm-originated molecule has been dosed in humans.
- No disclosed economic figures for partnerships.
- Headcount reportedly reduced from around 80 to 27 in 2025.
- Performance claims are self-generated and not replicated by a third party.
- Design results have appeared in preprint rather than peer review.
Based on reviews from: Standigm Website, AI Drug Discovery Platforms Built in Asia-Pacific, and What They Have Actually Shipped - August 3, 2026
Last updated: 2026-08-06
Videos
News, demos, and interviews about Standigm.
Videos load interactively. If none appear, search YouTube for Standigm →
Frequently Asked Questions
Related Companies
Rocket Systems is a software development company that creates innovative technology solutions, including AI tools, to accelerate business growth and enhance efficiency for various industries, including healthcare. For physicians and healthcare providers, Rocket Systems specializes in developing HIPAA-compliant AI solutions designed to streamline administrative tasks and improve patient care. These tools can assist with patient […]
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company that focuses on the discovery, development, and commercialization of prescription medicines. The company’s portfolio addresses major diseases in areas such as oncology, rare diseases, and biopharmaceuticals, which include cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca operates globally, with a significant commercial presence in […]
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]
Develop Health is a healthcare AI company that provides an electronic health record (EHR) platform utilizing generative artificial intelligence (AI) to automate benefits verification and prior authorization workflows for healthcare providers. The company’s technology aims to streamline administrative processes for medication access, significantly reducing the time spent on manual form completion—by more than 80%—and improving […]
MyTrials.ai is a healthcare AI company dedicated to revolutionizing access to clinical trials for patients and streamlining recruitment for researchers. The platform leverages artificial intelligence and clinical expertise to match patients with suitable clinical trials based on their health profiles, preferences, and values. This approach aims to simplify complex medical information, making it easier for […]